Newly diagnosed patients with cancer at increased risk for stroke
the ONA take:
According to a new study published in the journal Annals of Neurology, researchers at Weill Cornell Medical College in New York City, New York, have found that newly diagnosed patients with cancer, particularly those with more aggressive disease, are at an increased risk for stroke in the months following diagnosis.
For the study, researchers analzyed Medicare claims from 2001 to 2009 by patients who had been diagnosed with colorectal, prostate, breast, lung, and pancreatic cancer. Results showed that compared to seniors without cancer, those with cancer had a much risk for stroke, especially during the first 3 months following cancer diagnosis.
Patients with colorectal, lung, and pancreatic cancer had the highest risk of stroke, as those diseases are often more aggressive at the time of diagnosis. Those with breast and prostate cancer had the lowest risk for stroke as those diseases are typically diagnosed as localized tumors.
Although the study was not designed to determine why patients with cancer have an increased risk for stroke, the researchers suggest that cancer and the treatments for cancer affect the circulatory and coagulation systems. The researchers note that patients should be advised of the signs and symptoms of stroke as it can delay cancer treatment and cause disability and death.
Newly diagnosed patients with cancer are at an increased risk for stroke in the months following diagnosis.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|